Editor's Note: Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run — and has identified the top S&P 500 stock 12 years running. Today, he's giving away his #1 AI stock pick for 2026, free. Click here to get the name and ticker or read more below.

Dear Reader,

I want to give you a free stock pick today.

No strings attached. No credit card required. Just the name, ticker, and my full analysis.

Here's what I can tell you right now:

This company's sales are up 28% year over year. It holds over 30,000 patents in wireless and video technology. And it just earned an A-rating in my proprietary Stock Grader system.

That's the same system that helped me flag Nvidia back in 2005 — before its 82,000% run.

In fact, this system has identified the top-performing S&P 500 stock for 12 years running. Over the years, it has cost me $9 million to build and maintain. And right now, it's flashing its highest possible rating on this AI play.

Click here to see which AI stock my $9 million system is flagging right now, free.

But this pick is just the beginning...

I've also identified three more AI stocks my system shows have the same early-stage characteristics as Nvidia did in 2005.

Click here to get the name and ticker of my #1 AI stock for 2026 in this free briefing, completely free.

Regards,

Louis Navellier

Senior Investment Analyst, InvestorPlace

P.S. My Stock Grader system has cost $9 million to build and maintain. It helped me flag Nvidia at $1 split-adjusted. Today it's flashing its highest rating on one AI stock and I'm giving you the name free. Click here before this briefing comes down.

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

Author: Nathan Reiff. Originally Published: 4/17/2026.

Weight-loss drugs are big business. The GLP-1 receptor agonist market is expected to nearly triple to $185 billion by 2033, a compound annual growth rate of roughly 12.4%. Although this trend is global, the bulk of the market remains in the United States, and U.S. investors can access the growth by targeting companies that manufacture these drugs.

Don’t assume all GLP-1 sales will be dominated by Ozempic or Wegovy, both produced by pharma giant Novo Nordisk A/S (NYSE: NVO). Demand in this emerging space is so strong that many alternatives are appearing quickly, despite a few major players' high profile. Below, we highlight a lesser-known biotech with a promising candidate in development and two exchange-traded funds (ETFs) that offer broader, diversified exposure to the industry.

A Pivot Toward GLP-1 Drugs Could Be Transformational for Structure Therapeutics

Structure Therapeutics (NASDAQ: GPCR) is a biotechnology company focused on therapies targeting G protein-coupled receptors (GPCRs). Historically it worked on treatments for metabolic and inflammatory diseases such as fibrosis and nonalcoholic steatohepatitis.

More recently, Structure has shifted toward GLP-1 drugs. Its candidate aleniglipron has shown about 16.3% weight loss in trials after adjusting for certain factors, and it may offer advantages versus competitors on safety and manufacturing cost.

Though Structure is not yet profitable, it holds a healthy cash position of roughly $1.4 billion, which should provide runway as aleniglipron progresses toward a pivotal Phase 3 trial.

Analysts have noted Structure's potential based on aleniglipron's promise: 15 of 18 analyst ratings are Buy or equivalent. Shares have declined about 20% so far this year amid challenging external conditions, but the consensus price target of $110 implies the stock could more than double from current levels.

The First GLP-1 Agonist ETF Is Building a Track Record of Success

There is substantial potential in the GLP-1 space, as reflected by several ETFs that have launched to capture it. The Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM), which launched in mid-2024, was an early entrant. The actively managed fund takes a relatively focused approach, targeting roughly two dozen pharmaceutical companies positioned to benefit from GLP-1 growth.

Novo Nordisk and major rival Eli Lilly & Co. (NYSE: LLY) together account for nearly 30% of OZEM's portfolio. The fund also includes a mix of domestic and international names to provide geographic diversification.

Importantly, OZEM gives exposure not only to large drugmakers producing GLP-1 therapies but also to companies developing other weight-loss technologies and to firms supporting the supply chain vital for production.

As an active fund, OZEM charges an expense ratio of 0.59%. That is higher than many passive ETFs but competitive among active managers. The fund’s niche focus means it has a modest asset base—about $52 million—and relatively low trading volumes. Still, it has returned an impressive 45% over the past year, rewarding buy-and-hold investors. A modest dividend is an added perk.

Another GLP-1 ETF With a Passive Approach

A passive alternative is the Amplify Weight Loss Drug & Treatment ETF (NYSEARCA: THNR). Like OZEM, THNR charges a 0.59% annual fee and targets roughly two dozen pharmaceutical companies tied to the GLP-1 market. Novo Nordisk and Eli Lilly are significant holdings, but together they make up closer to about a quarter of the portfolio, leaving relatively more room for other names.

The key distinction is that THNR is not actively managed: it tracks an index of companies involved in GLP-1 and related treatments. Its weightings are determined by float-adjusted market capitalization and influenced by factors such as trading volume.

The index is rebalanced quarterly, and some investors may prefer this passive, market-reflective approach over active management.

That said, THNR’s asset base is very small—about $4 million—and trading volume is limited. The fund has returned roughly 30% over the last year, which is solid but below OZEM's performance.